Bristol-Myers Squibb Compnay

Cytomx Therapeutics, Inc.

Bonum Therapeutics, Inc.

The Rockefeller University

Shannon Lee Okada

Aaron Paul Yamniuk

Brigitte Devaux

Brenda L Stevens

Bryan C Barnhart

James William West

John Thomas Mulligan

Diane L Hollenbaugh

Justin Richard Killebrew

Jeffrey V Ravetch

Rony Dahan

Provided herein are protein complexes comprising a sensor domain and a therapeutic domain linked by a linker, and methods of use thereof. In aspects of the present disclosure, activity of the therapeutic domain comprises a dependence on sensor domain binding to target markers.

Compositions of protein complexes and methods of use thereof

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

Anti-CD40 antibodies and uses thereof

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc&#x3b3;RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

Nucleic acids encoding an anti-CD40 antibody

Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc&#x3b3;RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.

Antibodies to CD40 with enhanced agonist activity

Growing community of inventors

Seattle, WA, United States of America

Shannon Lee Okada